What is the recommended management and communication strategy for a patient with an atrial septal defect (ASD) and arrhythmogenic right ventricular dysplasia (ARVD)?

Management of ASD with ARVD

Patients with both ASD and ARVD require comprehensive hemodynamic evaluation before any ASD closure, with primary focus on optimizing ARVD management through ICD placement for high-risk features, beta-blockers, exercise restriction, and careful assessment of right ventricular function, as ASD closure could precipitate clinical deterioration in the setting of underlying RV disease. 1, 2

Critical Initial Assessment

Hemodynamic Evaluation Priority

• Perform comprehensive hemodynamic assessment before considering any ASD intervention, as the combination of ARVD with ASD creates complex RV physiology where closure could worsen outcomes 1, 2
• Evaluate for residual anatomic abnormalities, RV function, pulmonary artery pressures, and shunt quantification (Qp:Qs ratio) 1, 3
• Measure PA systolic pressure and pulmonary vascular resistance, as ASD closure is contraindicated when PA systolic pressure exceeds two-thirds systemic or pulmonary vascular resistance exceeds two-thirds systemic 1

ARVD-Specific Risk Stratification

• Assess for high-risk ARVD features including: unexplained syncope, frequent PVCs, ventricular tachycardia, QRS duration ≥180 ms, decreased ventricular function, or elevated BNP 2
• Perform electrophysiological study in patients with frequent or complex ventricular arrhythmias to guide management 2
• Obtain cardiac MRI with late gadolinium enhancement to characterize myocardial scar burden in both ventricles, as this is now a diagnostic hallmark of arrhythmogenic cardiomyopathy 4

Management Algorithm

ARVD Management Takes Priority

1. Sudden Cardiac Death Prevention

• Place ICD in patients with documented sustained VT, resuscitated cardiac arrest, or high-risk features (unexplained syncope with ventricular dysfunction) 2, 5
• Consider subcutaneous ICD given potential anatomic complexity, though complication rates are higher (26-45%) in congenital heart disease patients 2

2. Medical Therapy

• Initiate beta-blocker therapy for all ARVD patients to reduce arrhythmic burden 2, 5
• Mandate strict exercise restriction, as physical activity is a critical environmental factor for ARVD progression and arrhythmia risk 5, 6

3. Arrhythmia Management

• Consider catheter ablation for recurrent VT, though success may be limited by deep endocardial or LV origin of circuits 2
• Antiarrhythmic drugs serve as palliative adjuncts but do not replace ICD therapy 5

ASD Closure Decision-Making

Contraindications to ASD Closure in This Population:

• Do not close ASD if PA systolic pressure >2/3 systemic, pulmonary vascular resistance >2/3 systemic, or net right-to-left shunt present 1
• Defer ASD closure if RV dysfunction from ARVD would worsen with loss of the "pop-off" mechanism that the ASD provides for RV pressure relief 1, 2

When Closure May Be Considered:

• Only if Qp:Qs ≥1.5:1 with RV enlargement, no significant pulmonary hypertension, and stable ARVD with adequate RV function 1, 7
• Perform temporary balloon occlusion test during catheterization to assess hemodynamic tolerance before device closure, measuring left heart pressures 3
• Surgical closure may be preferred over percutaneous approach given need for direct visualization and potential for concomitant arrhythmia surgery 2

Diagnostic Workup Specifics

Imaging Requirements

• Transesophageal echocardiography to define ASD anatomy, size, and pulmonary venous connections 1
• Cardiac MRI with LGE for ARVD characterization and to exclude other cardiomyopathies 4
• Exercise pulse oximetry to detect shunt reversal with activity (desaturation to <90%) 1

Electrophysiological Assessment

• 12-lead ECG looking for epsilon waves, T-wave inversions in right precordial leads, QRS prolongation 5, 4
• Holter monitoring to quantify PVC burden and detect nonsustained VT 2
• Signal-averaged ECG may identify late potentials 5

Communication Strategy

Patient Counseling

• Explain that ARVD management supersedes ASD closure decisions, as sudden death prevention is the primary concern 2, 5
• Discuss that ASD closure may not be appropriate or may need indefinite deferral given RV disease 1, 2
• Emphasize mandatory exercise restriction for ARVD, which differs from typical ASD management where exercise is often encouraged post-closure 5, 6

Multidisciplinary Coordination

• Manage at tertiary center with adult congenital heart disease and electrophysiology expertise 7
• Coordinate care between ACHD cardiologists, electrophysiologists, and cardiac surgeons 2, 7
• Arrange genetic testing and family screening for ARVD, as desmosomal mutations are common 5, 4

Common Pitfalls

• Avoid routine ASD closure without considering the protective "pop-off" effect in RV disease - closure can precipitate acute RV failure 1, 2
• Do not rely solely on resting hemodynamics; exercise testing may unmask shunt reversal or RV dysfunction 1
• Recognize that standard ASD closure criteria do not apply when complex RV pathology coexists 1
• ICD complications are significantly higher in congenital heart disease (26-45% vs. standard populations), requiring careful device selection and implantation technique 2